Later-Line PD-1 Inhibitor Improves Melanoma Outcomes

Later-Line PD-1 Inhibitor Improves Melanoma Outcomes
More patients with advanced melanoma who had progressed on ipilimumab with or without a BRAF inhibitor were able to achieve an objective response when treated with the PD-1 immune checkpoint inhibitor nivolumab than with alternative chemotherapy …
Read more on Cancer Network

Immunotoxin Effectively Targets B-Cell Malignancies
In a phase I trial, DT2219, a modified diphtheria toxin bound to a variable fragment of antibodies targeting CD19 and CD22, has shown activity against relapsed and refractory B-cell lymphoma and leukemia. The results of this trial were published in …
Read more on Cancer Network

This entry was posted in Searchmedica and tagged , , , , . Bookmark the permalink.